Early Clinical Experience With Hydrophobic Acrylic IOL and Injector System in Patients at Risk for Intraocular Inflammation
To assess clinical outcomes in patients with cataract and concomitant intraocular inflammatory conditions after phacoemulsification and implantation of the enVista (Bausch + Lomb) MX60 hydrophobic acrylic intraocular lens (IOL) with the BLIS injector system.
A retrospective series of 50 eyes in 22 patients with cataract and concomitant controlled ocular inflammatory conditions (uveitis, keratitis, or previous ocular trauma) underwent phacoemulsification and implantation of the enVista IOL. All surgeries were performed by a single surgeon using BLIS (Bausch + Lomb Injector System), which was designed for use with the enVista IOL, comes with a reusable hand piece and single-use cartridges, and can deliver the IOL through unenlarged phaco incisions as small as 2.2 mm. Patients were followed for 3 months. Outcomes evaluated included postoperative best-corrected visual acuity (BCVA), anterior chamber (AC) cells, and IOL deposits.
BCVA at postoperative month 3 was 20/50 or better in 98% of eyes and 20/25 or better in 76% of eyes. MRSE was within ±1.0 D of target in 100% of eyes and within ±0.5 D of target in 88% of eyes. No IOL inflammatory deposits or glistenings were observed. IOL insertion was uncomplicated, and no wound leaks were noted.
Early clinical experience with the enVista IOL and BLIS suggests that this technology is appropriate for cataract patients at increased risk of intraocular inflammation. Month 3 BCVA and MRSE predictability were favorable, and there were no postoperative wound complications, and no IOL inflammatory deposits or glistenings.